Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Bausch Health Companies Inc (BHC.TO)

Bausch Health Companies Inc (BHC.TO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 12,866,403
  • Shares Outstanding, K 358,396
  • Annual Sales, $ 8,027 M
  • Annual Income, $ -560,000 K
  • 60-Month Beta 1.54
  • Price/Sales 1.26
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade BHC.TO with:

Options Overview

Details
  • Implied Volatility 44.44%
  • Historical Volatility 22.90%
  • IV Percentile 58%
  • IV Rank 49.22%
  • IV High 76.18% on 09/03/20
  • IV Low 13.68% on 04/08/21
  • Put/Call Vol Ratio 0.00
  • Today's Volume 6
  • Volume Avg (30-Day) 108
  • Put/Call OI Ratio 0.42
  • Today's Open Interest 5,336
  • Open Int (30-Day) 6,248

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/21
See More
  • Average Estimate 1.21
  • Number of Estimates 5
  • High Estimate 1.29
  • Low Estimate 1.13
  • Prior Year 0.65
  • Growth Rate Est. (year over year) +86.15%

Price Performance

See More
Period Period Low Period High Performance
1-Month
34.13 +3.66%
on 07/19/21
37.53 -5.73%
on 07/02/21
-1.40 (-3.81%)
since 06/25/21
3-Month
32.43 +9.10%
on 05/11/21
42.45 -16.65%
on 04/28/21
-3.34 (-8.63%)
since 04/27/21
52-Week
19.88 +77.97%
on 09/30/20
43.97 -19.54%
on 03/09/21
+11.31 (+46.99%)
since 07/27/20

Most Recent Stories

More News
Salix Announces 2021 Gastrointestinal Health Scholars Program Winners

/PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") and its gastroenterology business, Salix Pharmaceuticals, ("Salix"), one of the largest specialty pharmaceutical companies...

BHC : 28.12 (-1.78%)
BHC.TO : 35.50 (-1.11%)
Bausch + Lomb Will Present 14 Scientific Posters Featuring New Analyses Involving Its Surgical Technologies At The 2021 Annual Meeting Of The American Society Of Cataract And Refractive Surgery

/PRNewswire/ -- Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health"), today announced the presentation of 14 scientific posters involving...

BHC : 28.12 (-1.78%)
BHC.TO : 35.50 (-1.11%)
Bausch + Lomb Launches Biotrue® Hydration Boost Lubricant Eye Drops and Biotrue® Micellar Eyelid Cleansing Wipes

/PRNewswire/ -- Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health"), today announced the U.S. launch of Biotrue Hydration Boost Lubricant...

BHC : 28.12 (-1.78%)
BHC.TO : 35.50 (-1.11%)
Bausch + Lomb Completes Enrollment Of Second Phase 3 Study For NOV03 (perfluorohexyloctane)

and , , /PRNewswire/ -- Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company"), and Novaliq GmbH, a biopharmaceutical company...

BHC : 28.12 (-1.78%)
BHC.TO : 35.50 (-1.11%)
Bausch Health Companies Inc. Will Release Second-Quarter 2021 Financial Results On August 3

/PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") will release its second-quarter 2021 financial results on . Bausch Health will host a conference call and live web cast at...

BHC : 28.12 (-1.78%)
BHC.TO : 35.50 (-1.11%)
Bausch Health To Reduce Debt By $150 Million Using Cash Generated From Operations

/PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") today announced it will reduce debt by through the redemption of outstanding senior notes, using cash generated...

BHC : 28.12 (-1.78%)
BHC.TO : 35.50 (-1.11%)
Bausch + Lomb Expands Parameters for Bausch + Lomb ULTRA® Multifocal for Astigmatism Contact Lenses

 New Parameters Provide a Broader Offering for Presbyopic Patients with Astigmatism , QB, /PRNewswire/ -- Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. (NYSE/TSX:...

BHC : 28.12 (-1.78%)
BHC.TO : 35.50 (-1.11%)
Bausch Health Announces Extension Of Its Tender Offer For Cash Tender Offer For Senior Secured Notes By One Business Day To Reflect The Federal Holiday On June 18, 2021

/PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC)("Bausch Health," the "Company" or the "Offeror") today announced that it has extended the expiration date for its previously announced cash...

BHC : 28.12 (-1.78%)
BHC.TO : 35.50 (-1.11%)
Bausch Health Announces D. Robert Hale Has Resigned From Its Board Of Directors

/PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") today announced that D. has resigned from his role as an independent director of the Company's Board of...

BHC : 28.12 (-1.78%)
BHC.TO : 35.50 (-1.11%)
Bausch + Lomb and Lochan Enter Into Agreement to Develop the Next-Generation of eyeTELLIGENCE™ Clinical Decision Support Software

QB and , /PRNewswire/ -- Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health"), today announced that its affiliate has entered into an agreement...

BHC : 28.12 (-1.78%)
BHC.TO : 35.50 (-1.11%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Average short term outlook on maintaining the current direction.

See More Share

Key Turning Points

3rd Resistance Point 36.93
2nd Resistance Point 36.62
1st Resistance Point 36.26
Last Price 35.50
1st Support Level 35.59
2nd Support Level 35.28
3rd Support Level 34.92

See More

52-Week High 43.97
Last Price 35.50
Fibonacci 61.8% 34.77
Fibonacci 50% 31.92
Fibonacci 38.2% 29.08
52-Week Low 19.88

See More

Business Summary

Formerly known as Valeant Pharmaceuticals, Bausch Health is a global specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the dermatology, gastrointestinal, and ophthalmology markets. The company reports revenue in four segments: Bausch+Lomb and international...

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar